SKB103 / Sichuan Kelun Pharma - LARVOL DELTA

Study of SKB103 in HER2-negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=140 | Not yet recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • HER-2

SKB103 for Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=277 | Recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Sichuan Kelun-Biotech Biopharmaceutical…announced that the Investigational New Drug (IND) application for SKB103…has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors (PRNewswire) - "The approval marks SKB103 as the Company's first TAA-PD-L1 bsADC candidate and its second bsADC program for tumor therapy to enter the clinical stage, following SKB571."

Trial status • Solid Tumor

SKB103 for Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=277 | Not yet recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

New P1/2 trial • Oncology • Solid Tumor